KOSDAQBiotech & Pharma200670

Humedix

₩21,200▼ 2.08%2026-11-18 close
Market Cap
₩234.2B
Turnover
₩300M
Volume
10K
Shares out.
11.1M
PER
9.5×
PBR
0.8×
EPS
₩2,348
Dividend Yield
4.13%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩920 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Keeps Growing as Quarterly Profit Pauses

Humedix grew revenue and net income attributable to controlling shareholders through 2025, but that profit has fallen for two straight quarters since Q2 2026, leaving its earnings trend mixed.

  1. 1

    Q3 2026 revenue reached KRW 50.2 billion, up 22.8% year on year, and operating profit rose 11.3% to KRW 9.99 billion.

  2. 2

    Net income attributable to controlling shareholders fell 90.8% year on year to KRW 2.09 billion, reflecting a valuation loss on held financial assets.

  3. 3

    Annual revenue rose from KRW 123.2 billion in 2022 to KRW 170.1 billion in 2025, and operating profit peaked at KRW 43.1 billion in 2024 within the period.

  4. 4

    The debt-to-equity ratio fell from 63.3% in 2022 to 8.0% in 2025, with total equity of KRW 299.6 billion at year-end 2025.

  5. 5

    The company has said it will raise per-share dividends by 5 to 30% a year through 2028 under its mid- to long-term dividend policy.

02

Business structure

Humedix is an aesthetics specialist that started with hyaluronic acid (HA) fillers and has expanded into skin boosters, medical devices, cosmetics and contract manufacturing (CMO) for prescription drugs.

Its aesthetic lineup includes an ECM-based skin booster, a second skin booster, a PDLLA-based filler line, a radiofrequency medical device, a wound dressing and a plant-derived exosome product.

Its main customers are domestic medical clinics, and the company uses academic marketing aimed at clinicians, including its HART symposium, to drive sales. Q3 2026 revenue growth was led by wider supply of aesthetic products to domestic clinics and a rise in orders for over-the-counter eye drops.

The company is also widening distribution channels for its cosmetics line in Korea and abroad. In prescription drugs, it began exporting an osteoarthritis injection to Brazil and is expanding into Russia, the CIS and Southeast Asia.

In September 2026 it acquired a 51% stake in an influencer and data-driven marketing company and consolidated it from Q3, aiming to link digital marketing with its medical aesthetics, cosmetics and health functional food businesses.

On the competitive side, intensifying rivalry among domestic aesthetics firms slowed growth in filler and botulinum toxin sales in Q1 2026. It competes in the medical aesthetics market with peers in the same sector such as Hugel and PharmaResearch.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩40.9B₩9B21.9%
2025Q4₩46B₩11.1B24.2%
2026Q1₩40.5B₩8.9B22.0%
2026Q2₩50.4B₩11.7B23.2%
2026Q3₩50.2B₩10B19.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩123.2B₩26B₩21.2B21.1%15.2%63.3%
2023₩152.3B₩37.3B₩24.8B24.5%12.5%11.1%
2024₩161.9B₩43.1B₩39.3B26.7%17.2%9.3%
2025₩170.1B₩42.3B₩51.8B24.9%17.3%8.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 123.2 billion in 2022 to KRW 170.1 billion in 2025, with three straight years of growth from 2023 through 2025. Growth slowed from 23.6% in 2023 to 6.3% in 2024 and 5.1% in 2025.

Operating profit climbed from KRW 26 billion in 2022 to KRW 37.3 billion in 2023 and KRW 43.1 billion in 2024, the peak year of the period, before falling 1.9% to KRW 42.3 billion in 2025. The operating margin rose from 21.1% in 2022 to 26.7% in 2024 and eased to 24.9% in 2025.

Net income attributable to controlling shareholders grew from KRW 21.2 billion in 2022 to KRW 51.8 billion in 2025, including a 31.9% increase in 2025.

Operating profit fell in 2025 while this earnings line rose, which suggests non-operating items may have contributed, and the next annual report will show the composition. Operating cash flow dropped from KRW 50.7 billion in 2024 to KRW 45.1 billion in 2025.

On a quarterly basis, revenue fell from KRW 46 billion in Q4 2025 to KRW 40.5 billion in Q1 2026 before recovering to KRW 50.4 billion in Q2, which the company described as its highest quarterly revenue on record.

The Q1 2026 decline in operating profit was attributed to lower filler sales and higher selling and administrative expenses.

Net income attributable to controlling shareholders fell from KRW 22.7 billion in Q3 2025 to KRW 7.81 billion in Q4 2025, recovered to KRW 13 billion in Q1 2026, then fell for two straight quarters to KRW 2.45 billion in Q2 and KRW 2.09 billion in Q3 2026.

Q3 2026 net income reflected a valuation loss on held financial assets, and the combined figure for the last four quarters is KRW 25.3 billion.

05

Industry analysis

Korea's aesthetics market is shifting from a filler-centered structure toward wider lineups that include skin boosters, medical devices and cosmetics. Humedix has pursued portfolio diversification around its ECM-based skin booster line.

A January 2026 report from Sangsangin Securities said sales of that product were growing quickly as clinical reluctance eased. At the same time, intensifying competition among domestic aesthetics companies has slowed growth in fillers and botulinum toxin.

In comparisons with peers in the same sector, such as Hugel and PharmaResearch, the pace of new product launches appears to be the key variable. On exports, a January 2026 press report cited plans to expand entry into the Middle East and South America.

Filler export recovery was framed as dependent on diversifying the number of export countries to reduce reliance on any single market. Contract manufacturing of prescription drugs, alongside exports of an osteoarthritis injection, is another axis diversifying the business structure.

Where the industry sits in its cycle is hard to judge from filings alone, so quarterly revenue trends and competitors' launch timing are the practical reference points.

06

Outlook

In the second half of 2026, the company plans to expand distribution of its ECM-based skin booster line and a follow-on product, and to increase sales of its filler line.

It also intends to broaden its aesthetics lineup with a radiofrequency device, a wound dressing and an exosome product, and to launch new products together with aesthetics partners while expanding sales channels.

Its composite filler combining polynucleotide sodium and HA applied for domestic product approval in May 2026, and the company aims to launch it within 2026. In cosmetics, it is pursuing pharmacy sales of its ECM cosmetic line and wider distribution at home and abroad.

In prescription drugs, after starting exports of an osteoarthritis injection to Brazil, it plans to enter Russia, the CIS and Southeast Asia. Contract manufacturing is expected to add orders as the product mix broadens.

Consolidation of the marketing company is intended to link digital marketing with the group's other businesses. The revenue contribution of these plans will show up in quarterly results and periodic reports over time.

The next checkpoints are whether the composite filler is approved and launched, and the revenue mix in the 2026 annual report.

07

Valuation

PER
9.5×
PBR
0.8×
ROE
8.9%
EPS
₩2,348
BPS
₩29,642
Dividend per share
₩920

The price-to-book ratio sits below 1x, which means the shares trade at a discount to net asset value. Earnings multiples are sensitive to quarterly swings.

Net income attributable to controlling shareholders over the last four quarters totals KRW 25.3 billion, and the drop from KRW 22.7 billion in Q3 2025 to KRW 7.81 billion in Q4 2025 shows how wide quarterly variation can be. Q3 2026 earnings were lower than operating trends because of a financial-asset valuation loss.

The company's policy to raise per-share dividends by 5 to 30% a year through 2028 means the dividend yield is best read alongside that expected path. Total liabilities of KRW 24.1 billion at year-end 2025 are small relative to equity, so balance-sheet strain is not the main variable in valuation.

Because the operating margin fell from 26.7% in 2024 to 24.9% in 2025, the recovery of that margin is the key factor for reading valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Broader aesthetics lineup

A wider lineup of skin boosters, medical devices and cosmetics lifted Q3 2026 revenue to KRW 50.2 billion, up 22.8% year on year. The company credited expanded supply to domestic clinics and academic marketing. Q2 2026 revenue of KRW 50.4 billion was, by the company's account, its highest quarterly figure on record. Added capacity for its ECM-based skin booster supported sales in that quarter.

Low leverage

The debt-to-equity ratio fell from 63.3% in 2022 to 8.0% in 2025, with total equity of KRW 299.6 billion and total liabilities of KRW 24.1 billion at year-end 2025. Operating cash flow stayed at a high level, moving from KRW 38.1 billion in 2022 to KRW 45.1 billion in 2025.

This financial capacity supports marketing investment, capacity expansion and the cost of fulfilling export contracts.

Mid- to long-term shareholder returns

Under its mid- to long-term dividend policy, the company has said it plans to raise per-share dividends by 5 to 30% a year through 2028. The payouts are funded by reducing capital reserves, which the company said could give shareholders tax-exempt treatment. The record date for the Q3 2026 dividend is December 4, 2026.

09

Bear factors

Consecutive quarterly profit declines

Net income attributable to controlling shareholders fell from KRW 13 billion in Q1 2026 to KRW 2.45 billion in Q2 and KRW 2.09 billion in Q3, two consecutive quarterly declines. Q3 net income was down 90.8% year on year, which the company linked to a valuation loss on held financial assets.

Over the same period operating profit rose 11.3% year on year to KRW 9.99 billion in Q3, so the operating and net income lines moved in different directions.

Slower filler and toxin growth

In its Q1 2026 results, the company said fewer sales of some prescription drugs, including arthritis treatments, and intensifying competition among domestic aesthetics firms slowed growth in filler and botulinum toxin revenue.

Operating profit for that quarter fell because filler sales declined and selling and administrative costs rose. If competition pushes firms to widen their lineups and step up marketing, cost pressure could increase as well.

2025 operating profit decline and margin slippage

Revenue in 2025 rose 5.1% to KRW 170.1 billion, but operating profit fell 1.9% to KRW 42.3 billion. The operating margin declined from 26.7% in 2024 to 24.9% in 2025.

Net income attributable to controlling shareholders rose 31.9% in the same year, diverging from the operating trend, and non-operating items together with selling and administrative cost trends are the key variables behind that gap.

10

Risk factors

Financial asset valuation

Net income can move independently of operating trends depending on how held financial assets are valued. In Q3 2026 a valuation loss pushed net income attributable to controlling shareholders sharply lower. This volatility means operating profit has to be read alongside net income in any quarterly analysis.

Approval and launch timing

The composite filler combining polynucleotide sodium and HA applied for domestic approval in May 2026 and is targeted for launch within the year. Any delay in approval would push back the expansion of the filler lineup and the second-half sales plan. The sales pace of new products will depend on academic marketing and distribution access.

Integration and competition

The company acquired a 51% stake in an influencer and data-driven marketing firm in September 2026 and consolidated it from Q3, with plans to link its digital marketing with group businesses. The timing and size of any contribution to results will need to be confirmed in quarterly disclosures.

If competition among domestic aesthetics companies persists, slower growth in fillers and toxins could last longer.

11

What to watch next

  1. December 4, 2026

    Record date for the Q3 2026 dividend. This is the point to confirm that shareholder returns under the mid- to long-term policy are being paid for the quarter.

  2. By year-end 2026

    Whether the composite filler Valpien receives domestic approval and launches within the year as targeted. This is the starting point for judging whether the broader filler line contributes to 2027 results.

  3. By end-March 2027

    Deadline for the 2026 annual report. Annual revenue, operating profit, net income attributable to controlling shareholders and the operating margin will be compared with the 24.9% recorded in 2025, and Q4 figures will be confirmed as disclosed results.

  4. Each year from 2027 through 2028

    Whether the annual board decisions carry out the per-share dividend increases under the mid- to long-term policy. Where each increase falls within the 5 to 30% range will show the actual strength of shareholder returns.

12

Overall view

Humedix's revenue rose from KRW 123.2 billion in 2022 to KRW 170.1 billion in 2025, and net income attributable to controlling shareholders also grew on an annual basis over the same period. In 2025 operating profit fell 1.9%, pulling the operating margin down to 24.9%.

Revenue held at a high level in Q2 and Q3 2026 at KRW 50.4 billion and KRW 50.2 billion, but net income attributable to controlling shareholders has declined for two straight quarters since Q1 2026's KRW 13 billion. By the company's account, the Q3 net income decline reflects a valuation loss on held financial assets.

Strengths include the broader product lineup, low leverage and a dividend policy that raises payouts through 2028. Weaknesses include slower filler and toxin growth amid intensifying domestic competition, a declining operating margin trend and net income swings from valuation gains and losses.

The next checkpoints are the December 4, 2026 dividend record date, whether the composite filler launches by year-end 2026, and the 2026 annual report due by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. ebn.co.kr
  2. m.sedaily.com
  3. inthenews.co.kr
  4. kr.investing.com
  5. medicopharma.co.kr
  6. m.news.nate.com
  7. news1.kr
  8. koreadaily.com
  9. m.dailypharm.com
  10. huonsglobal.com
  11. humedix.com
  12. huonsglobal.com
  13. m.ddaily.co.kr
  14. view.asiae.co.kr
  15. edaily.co.kr
  16. huonsglobal.com
  17. etoday.co.kr
  18. tfmedia.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis